deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03228394

A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression

A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression

Sponsor: Marinus Pharmaceuticals

Conditions Behavioral Symptoms Depression Depression, Postpartum Depressive Disorder Mental Disorders Mood Disorders PPD Postpartum Pregnancy Complications Puerperal Disorders
Interventions Ganaxolone Placebo
Updated 16 times since 2017 Last updated: Jul 4, 2023 Started: Jun 27, 2017 Primary completion: May 10, 2019 Completion: May 10, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Behavioral Symptoms and Depression, this trial is completed. The trial is conducted by Marinus Pharmaceuticals and has accumulated 16 data snapshots since 2017. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Mar 2018 · 6 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jul 2019 · 8 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Aug 2023 · 5 months · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Aug 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Mar 2023 — Aug 2023 [monthly]

    Completed PHASE2

  5. Apr 2022 — Mar 2023 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Sep 2020 — Oct 2020 [monthly]

    Completed PHASE2

  4. Jun 2020 — Sep 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Apr 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Jul 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Nov 2018 — Jul 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  9. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  10. Sep 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  11. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Marinus Pharmaceuticals
Data source: Marinus Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Costa Mesa, United States , Dayton, United States , Decatur, United States , Houston, United States , Irving, United States , Jacksonville, United States , Leawood, United States , Lemon Grove, United States , Little Rock, United States and 6 more locations